The use of multigene sequencing as a therapeutic decision tool improved outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), according to results from the SAFIR02-BREAST trial.
Shutting down a gene called PRMT5 stopped metastatic estrogen receptor-positive breast cancer cells from growing after they acquired resistance to a standard therapy known as CDK4/6 inhibitors, UT Southwestern Medical Center researchers showed in a new study.
